Physician profile
Krista Larson
NPI 1245693902
$1,389.35
in general payments reported to CMS, 2019-2025
11 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.15 · 2022: $429 · 2023: $488 · 2024: $172 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.16 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $249.86 | 2021-2025 | |
| Janssen Biotech, INC. | $99.00 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $75.81 | 2022-2024 | Sotyktu |
| Pfizer INC. | $64.65 | 2023-2024 | |
| Genzyme Corporation | $38.18 | 2023 | |
| Amgen INC. | $35.60 | 2022-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $33.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $32.14 | 2023 | |
| Leo Pharma INC. | $29.33 | 2025 | Anzupgo |
| Organon LLC | $26.20 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.